about
Caspase activation is required for terminal erythroid differentiationTreatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience.Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation.Thrombocytemia and abnormal megakaryopoiesis associated with abnormality of chromosome 1p34 in myelodysplastic syndromes.Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection.Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupPI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy.Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot.Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review.High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionPim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Control of Pim2 kinase stability and expression in transformed human haematopoietic cellsHelical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot studyChromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature.The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.Hemophagocytic histiocytosis (HH) in renal transplant recipients under ciclosporin therapy: report of the first two cases.Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutationTargeting glutamine uptake in AMLThe LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 triChronic myelomonocytic leukemia associated with generalized myasthenia gravis.Large granular lymphocyte leukemia associated with hepatitis C virus infection and B cell lymphoma: improvement after antiviral therapy.Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation.[Castleman's disease (giant lymph node hyperplasia): clinical, biological and developing polymorphism. Apropos of 4 cases].
P50
Q24290854-EE025EBC-5B23-45A4-96E9-4A0C26108AC8Q33314465-4331FC57-B96F-404E-B42E-831F07B21DA9Q33395464-5793A753-F69A-4A4B-B6C1-E274DE6306F9Q33496766-9B9B2773-519F-4ED8-AAF5-638C8480ADABQ33497502-98A77A17-15DC-4B6A-9D0A-7F340794DD1EQ33501371-C674841F-0038-489F-9C69-513AB7D8274FQ33503127-4320CC1E-D00F-4187-995B-5C2ACF5D7B51Q33558123-894BD534-AA50-401B-9B82-94654CB8EC66Q34164683-72F56F43-ECEE-41F5-AE59-3C919897F160Q34750609-D45FC27B-3611-4F27-B9F5-0094C5FAB681Q34918221-5131554F-6DBB-4A33-BC04-E2D8730D5DF3Q35089572-1A1C4DAE-724B-43CE-80F7-4E91B7CA2EACQ35596914-7765D39D-8AC8-485B-9CE6-1A654EDAA659Q35717799-4E197495-B314-497E-AC27-14CAD896876BQ36169778-6F2AB998-3D91-4719-B883-ABC0D119DF59Q36276942-3F8D06D3-FB52-44F7-BC97-BAE38405F408Q36353641-E9F11297-C8D6-44DB-B8B9-02D4C25C7F0DQ36955623-AF3171DF-1976-4470-A1AB-C7BA43183E62Q37033951-62AC289A-6F10-4C43-8B53-CFDE3E05F0F6Q37311260-3DAC27B6-C77F-45C6-A198-6F5E902E32E4Q37349113-DB7FD495-EF3F-48B3-B36E-6618E12FD3B2Q37638749-68D3F1CE-8D76-4D77-B443-D1DDEDFA597EQ37642294-C4CD297B-5CAF-497F-AB78-DEE92B06048BQ37875635-F8E79D90-7DE4-4918-9260-B7D9C1DBA918Q37990030-DFA81849-0AC1-4E5E-B36A-6EE2B14104FAQ39363181-B066388C-A35B-4A1E-B9C6-7F6BCA164EC1Q39673732-C165E1D4-66EE-4AF0-98A6-8603AAFE3047Q39832054-56C4561F-1138-4DCA-98A4-CAB30A100760Q40687242-93FF2141-DB08-4DE1-AF2F-2E80816D236DQ41080080-11ED4916-1F05-4ECF-8CB1-07A8A42BD424Q41948671-DE1CF654-A65E-4D8D-A590-9D499488FD29Q42018487-B7DEC2C3-4B95-46C5-BD97-A0DB272404D2Q42953330-CEA30D92-AE48-40A1-98B6-78EEB4174512Q43051935-069D10A2-27C1-4963-B4D1-E93C11825CE0Q43456314-59D19BA7-F3FC-42FE-B116-9F243C2C1433Q43460831-A4A10F47-076D-45F7-9A5C-42026C362216Q43829965-1CB4A6BF-BA90-4907-82EE-AC39A4F74815Q43893064-1F4EFC25-A5A6-4595-8C9B-E90936A4A437Q44265467-4EA00195-CF64-418C-A620-B85B425100D5Q44595728-36D570A7-A2DF-48E4-9072-3CF0F422A447
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Didier Bouscary
@ast
Didier Bouscary
@en
Didier Bouscary
@es
Didier Bouscary
@nl
Didier Bouscary
@sl
type
label
Didier Bouscary
@ast
Didier Bouscary
@en
Didier Bouscary
@es
Didier Bouscary
@nl
Didier Bouscary
@sl
prefLabel
Didier Bouscary
@ast
Didier Bouscary
@en
Didier Bouscary
@es
Didier Bouscary
@nl
Didier Bouscary
@sl
P106
P21
P31
P496
0000-0003-3654-5064
P569
2000-01-01T00:00:00Z